Prof Kairbaan Hodivala-Dilke
Professor
Barts Cancer Institute
Faculty of Medicine and Dentistry, Queen Mary University of London
Faculty of Medicine and Dentistry, Queen Mary University of London
Research
Interests
Modelling the TME for human relevant therapy testsPublications
Publications of specific relevance to Predictive in vitro Models
2024
Guelfi S, Hodivala-Dilke K and Bergers G (2024). Targeting the tumour vasculature: from vessel destruction to promotion. Springer Nature Nature Reviews Cancer vol. 24, (10) 655-675.
Njegić A, Laid L, Zi M, Maniati E, Wang J, Chelu A, Wisniewski L, Hunter J, Prehar S, Stafford N, Gilon C, Hoffman A, Weinmüller M, Kessler H, Cartwright EJ and Hodivala-Dilke K (2024). Treatment with αvβ3-integrin-specific 29P attenuates pressure-overload induced cardiac remodelling after transverse aortic constriction in mice. Elsevier Journal of Molecular and Cellular Cardiology Plus vol. 8,
2023
Reynolds LE, Maallin S, Haston S, Martinez‐Barbera JP, Hodivala‐Dilke KM and Pedrosa A (2023). Effects of senescence on the tumour microenvironment and response to therapy. Wiley The FEBS Journal vol. 291, (11) 2306-2319.
Lechertier T, Reynolds LE, Kim H, Pedrosa AR, Gómez-Escudero J, Muñoz-Félix JM, Batista S, Dukinfield M, Demircioglu F, Wong PP, Matchett KP, Henderson NC, D’Amico G, Parsons M, Harwood C, Meier P and Hodivala-Dilke KM (2023). Author Correction: Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth. Springer Nature Nature Communications vol. 14, (1)
2022
Hübers C, Pari AAA, Grieshober D, Petkov M, Schmidt A, Messmer T, Heyer CM, Schölch S, Kapel SS, Gengenbacher N, Singhal M, Schieb B, Fricke C, Will R, Remans K, Utikal JS, Reissfelder C, Schlesner M, Hodivala-Dilke KM, Kersten S, Goerdt S, Augustin HG and Felcht M (2022). Primary tumor–derived systemic nANGPTL4 inhibits metastasis. Rockefeller University Press Journal of Experimental Medicine vol. 220, (1)
D'Amico G, Fernandez I, Gómez-Escudero J, Kim H, Maniati E, Azman MS, Mardakheh FK, Serrels B, Serrels A, Parsons M, Squire A, Birdsey GM, Randi AM, Bolado-Carrancio A, Gangeswaran R, Reynolds LE, Bodrug N, Wang Y, Wang J, Meier P and Hodivala-Dilke KM (2022). ERG activity is regulated by endothelial FAK coupling with TRIM25/USP9x in vascular patterning. The Company of Biologists Development vol. 149, (13)
Roy-Luzarraga M, Reynolds LE, de Lux�n-Delgado B, Maiques O, Wisniewski L, Newport E, Rajeeve V, Drake RJG, G�mez-Escudero JS, Richards FM, Weller CL, Dormann C, Meng Y-M, Vermeulen PB, Saur D, Sanz-Moreno V, Wong P-P, G�raud C, Cutillas PR and Hodivala-Dilke KM (2022). Suppression of endothelial cell FAK expression reduces pancreatic ductal adenocarcinoma metastasis after gemcitabine treatmentEC FAK regulates gemcitabine treated liver metastasis. American Association for Cancer Research (AACR) Cancer Research vol. 82, (10) 1909-1925.
Murray ER, Menezes S, Henry JC, Williams JL, Alba-Castellón L, Baskaran P, Quétier I, Desai A, Marshall JJT, Rosewell I, Tatari M, Rajeeve V, Khan F, Wang J, Kotantaki P, Tyler EJ, Singh N, Reader CS, Carter EP, Hodivala-Dilke K, Grose RP, Kocher HM, Gavara N, Pearce O, Cutillas P, Marshall JF and Cameron AJM (2022). Disruption of pancreatic stellate cell myofibroblast phenotype promotes pancreatic tumor invasion. Elsevier Cell Reports vol. 38, (4)
2021
Newport E, Pedrosa AR, Lees D, Dukinfield M, Carter E, Gomez‐Escudero J, Casado P, Rajeeve V, Reynolds LE, Cutillas PR, Duffy SW, De Luxán Delgado B and Hodivala‐Dilke K (2021). Elucidating the role of the kinase activity of endothelial cell focal adhesion kinase in angiocrine signalling and tumour growth. Wiley The Journal of Pathology vol. 256, (2) 235-247.
Newport EL, Pedrosa AR, Njegic A, Hodivala-Dilke KM and Muñoz-Félix JM (2021). Improved Immunotherapy Efficacy by Vascular Modulation. MDPI Cancers vol. 13, (20)
Lees DM, Reynolds LE, Pedrosa AR, Roy-Luzarraga M and Hodivala-Dilke KM (2021). Correction to: Phosphorylation of pericyte FAK‑Y861 affects tumour cell apoptosis and tumour blood vessel regression. Springer Nature Angiogenesis vol. 24, (3) 483-487.
Lees DM, Reynolds LE, Pedrosa AR, Roy-Luzarraga M and Hodivala-Dilke KM (2021). Phosphorylation of pericyte FAK-Y861 affects tumour cell apoptosis and tumour blood vessel regression. Springer Nature Angiogenesis vol. 24, (3) 471-482.
Delvecchio FR, Fincham REA, Spear S, Clear A, Roy-Luzarraga M, Balkwill FR, Gribben JG, Bombardieri M, Hodivala-Dilke K, Capasso M and Kocher HM (2021). Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice. Elsevier Cellular and Molecular Gastroenterology and Hepatology vol. 12, (5) 1543-1565.
2020
Roy-Luzarraga M, Reynolds L and Hodivala-Dilke K (2020). Regulation of tumour progression and metastasis by Endothelial-FAK upon chemotherapy treatment. Elsevier Pancreatology vol. 20, (8)
Roy-Luzarraga M, Abdel-Fatah T, Reynolds LE, Clear A, Taylor JG, Gribben JG, Chan S, Jones L and Hodivala-Dilke K (2020). Association of Low Tumor Endothelial Cell pY397–Focal Adhesion Kinase Expression With Survival in Patients With Neoadjuvant-Treated Locally Advanced Breast Cancer. American Medical Association (AMA) JAMA Network Open vol. 3, (10)
Abdul Pari AA, Singhal M, Hübers C, Mogler C, Schieb B, Gampp A, Gengenbacher N, Reynolds LE, Terhardt D, Géraud C, Utikal J, Thomas M, Goerdt S, Hodivala-Dilke KM, Augustin HG and Felcht M (2020). Tumor Cell–Derived Angiopoietin-2 Promotes Metastasis in Melanoma. American Association for Cancer Research (AACR) Cancer Research vol. 80, (12) 2586-2598.
Lechertier T, Reynolds LE, Kim H, Pedrosa AR, Gómez-Escudero J, Muñoz-Félix JM, Batista S, Dukinfield M, Demircioglu F, Wong PP, Matchett KP, Henderson NC, D’Amico G, Parsons M, Harwood C, Meier P and Hodivala-Dilke KM (2020). Pericyte FAK negatively regulates Gas6/Axl signalling to suppress tumour angiogenesis and tumour growth. Springer Nature Nature Communications vol. 11, (1)
Wong P-P, Muñoz-Félix JM, Hijazi M, Kim H, Robinson SD, De Luxán-Delgado B, Rodríguez-Hernández I, Maiques O, Meng Y-M, Meng Q, Bodrug N, Dukinfield MS, Reynolds LE, Elia G, Clear A, Harwood C, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Matchett KP, Henderson NC, Szlosarek PW, Dreger SA, Smith S, Jones JL, Gribben JG, Cutillas PR and Meier P (2020). Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells. Elsevier Cell vol. 181, (6) 1346-1363.e21.
Demircioglu F, Wang J, Candido J, Costa ASH, Casado P, de Luxan Delgado B, Reynolds LE, Gomez-Escudero J, Newport E, Rajeeve V, Baker A-M, Roy-Luzarraga M, Graham TA, Foster J, Wang Y, Campbell JJ, Singh R, Zhang P, Schall TJ, Balkwill FR, Sosabowski J, Cutillas PR, Frezza C, Sancho P and Hodivala-Dilke K (2020). Cancer associated fibroblast FAK regulates malignant cell metabolism. Nature Research (part of Springer Nature) Nature Communications vol. 11, (1) 1290-1290.
Wilcz‐Villega E, Carter E, Ironside A, Xu R, Mataloni I, Holdsworth J, Jones W, Moreno Béjar R, Uhlik L, Bentham RB, Godinho SA, Dalli J, Grose R, Szabadkai G, Jones L, Hodivala‐Dilke K and Bianchi K (2020). Macrophages induce malignant traits in mammary epithelium via IKKε/TBK1 kinases and the serine biosynthesis pathway. Springer Nature EMBO Molecular Medicine vol. 12, (2)
2019
D'Amico G, Muñoz‐Félix JM, Pedrosa AR and Hodivala‐Dilke KM (2019). “Splitting the matrix”: intussusceptive angiogenesis meets MT1‐MMP. Springer Nature EMBO Molecular Medicine vol. 12, (2)
Dukinfield M, Maniati E, Reynolds LE, Aubdool A, Baliga RS, D'Amico G, Maiques O, Wang J, Bedi KC, Margulies KB, Sanz‐Moreno V, Hobbs A and Hodivala‐Dilke K (2019). Repurposing an anti‐cancer agent for the treatment of hypertrophic heart disease. Wiley The Journal of Pathology vol. 249, (4) 523-535.
Li J, Fukase Y, Shang Y, Zou W, Muñoz-Félix JM, Buitrago L, van Agthoven J, Zhang Y, Hara R, Tanaka Y, Okamoto R, Yasui T, Nakahata T, Imaeda T, Aso K, Zhou Y, Locuson C, Nesic D, Duggan M, Takagi J, Vaughan RD, Walz T, Hodivala-Dilke K, Teitelbaum SL, Arnaout MA, Filizola M, Foley MA and Coller BS (2019). Novel Pure αVβ3 Integrin Antagonists That Do Not Induce Receptor Extension, Prime the Receptor, or Enhance Angiogenesis at Low Concentrations. American Chemical Society (ACS) ACS Pharmacology & Translational Science vol. 2, (6) 387-401.
Pedrosa A-R, BODRUG N, Gomez-Escudero J, Carter EP, Reynolds LE, Georgiou PN, Fernandez I, Lees DM, Kostourou V, Alexopoulou AN, Batista S, Tavora B, Serrels B, Parsons M, Iskratsch T and Hodivala-Dilke K (2019). Tumour angiogenesis is differentially regulated by endothelial cell Focal Adhesion Kinase tyrosine-397 and -861 phosphorylation. American Association for Cancer Research Cancer Research
Li Z, Solomonidis EG, Meloni M, Taylor RS, Duffin R, Dobie R, Magalhaes MS, Henderson BEP, Louwe PA, D’Amico G, Hodivala-Dilke KM, Shah AM, Mills NL, Simons BD, Gray GA, Henderson NC, Baker AH and Brittan M (2019). Single-cell transcriptome analyses reveal novel targets modulating cardiac neovascularization by resident endothelial cells following myocardial infarction. Oxford University Press (OUP) European Heart Journal vol. 40, (30) 2507-2520.
Moyes AJ, Chu SM, Aubdool AA, Dukinfield MS, Margulies KB, Bedi KC, Hodivala-Dilke K, Baliga RS and Hobbs AJ (2019). C-type natriuretic peptide co-ordinates cardiac structure and function. Oxford University Press (OUP) European Heart Journal vol. 41, (9) 1006-1020.
2018
Foxler DE, Bridge KS, Foster JG, Grevitt P, Curry S, Shah KM, Davidson KM, Nagano A, Gadaleta E, Rhys HI, Kennedy PT, Hermida MA, Chang T-Y, Shaw PE, Reynolds LE, McKay TR, Wang H-W, Ribeiro PS, Plevin MJ, Lagos D, Lemoine NR, Rajan P, Graham TA, Chelala C, Hodivala-Dilke KM, Spendlove I and Sharp TV (2018). A HIF-LIMD1 negative feedback mechanism mitigates the pro-tumorigenic effects of hypoxia. EMBO Mol Med
2017
Weinmüller M, Rechenmacher F, Marelli UK, Reichart F, Kapp TG, Räder AFB, Di Leva FS, Marinelli L, Novellino E, Muñoz‐Félix JM, Hodivala‐Dilke K, Schumacher A, Fanous J, Gilon C, Hoffman A and Kessler H (2017). Overcoming the Lack of Oral Availability of Cyclic Hexapeptides: Design of a Selective and Orally Available Ligand for the Integrin αvβ3. Wiley Angewandte Chemie International Edition vol. 56, (51) 16405-16409.
Alexopoulou AN, Lees DM, Bodrug N, Lechertier T, Fernandez I, D'Amico G, Dukinfield M, Batista S, Tavora B, Serrels B and Hodivala‐Dilke K (2017). Focal Adhesion Kinase (FAK) tyrosine 397E mutation restores the vascular leakage defect in endothelium‐specific FAK‐kinase dead mice. Wiley The Journal of Pathology vol. 242, (3) 358-370.
Ross JA, Webster RG, Lechertier T, Reynolds LE, Turmaine M, Bencze M, Jamshidi Y, Cetin H, Muntoni F, Beeson D, Hodilvala-Dilke K and Conti FJ (2017). Multiple roles of integrin-α3 at the neuromuscular junction. The Company of Biologists Journal of Cell Science vol. 130, (10) 1772-1784.
Reynolds LE, D'Amico G, Lechertier T, Papachristodoulou A, Muñoz-Félix JM, De Arcangelis A, Baker M, Serrels B and Hodivala-Dilke KM (2017). Dual role of pericyte α6β1-integrin in tumour blood vessels. The Company of Biologists Journal of Cell Science vol. 130, (9) 1583-1595.
(2017). Correction: A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. American Association for Cancer Research (AACR) Clinical Cancer Research vol. 23, (3) 870-870.
2016
Wong P-P, Bodrug N and Hodivala-Dilke KM (2016). Exploring Novel Methods for Modulating Tumor Blood Vessels in Cancer Treatment. Elsevier Current Biology vol. 26, (21) r1161-r1166.
Demircioglu F and Hodivala-Dilke K (2016). αvβ3 Integrin and tumour blood vessels—learning from the past to shape the future. Elsevier Current Opinion in Cell Biology vol. 42, 121-127.
Roy-Luzarraga M and Hodivala-Dilke K (2016). Molecular Pathways: Endothelial Cell FAK--A Target for Cancer Treatment. American Association for Cancer Research Clinical Cancer Research vol. 22, (15) 3718-3724.
Di Maggio F, Arumugam P, Delvecchio FR, Batista S, Lechertier T, Hodivala-Dilke K and Kocher HM (2016). Pancreatic stellate cells regulate blood vessel density in the stroma of pancreatic ductal adenocarcinoma. Elsevier Pancreatology
Dvorkina M, Nieddu V, Chakelam S, Pezzolo A, Cantilena S, Leite AP, Chayka O, Regad T, Pistorio A, Sementa AR, Virasami A, Barton J, Montano X, Lechertier T, Brindle N, Morgenstern D, LE Bras M, Burns A, Saunders N, Hodivala-Dilke K, Bagella L, de The H, Anderson J, Sebire N, Pistoia V, Sala A and Salomoni P (2016). A promyelocytic leukemia protein-thrombospondin 2 axis and the risk of relapse in neuroblastoma. American Association for Cancer Research Clinical Cancer Research
2015
Martins VL, Caley MP, Moore K, Szentpetery Z, Marsh ST, Murrell DF, Kim MH, Avari M, McGrath JA, Cerio R, Kivisaari A, Kähäri VM, Hodivala-Dilke K, Brennan CH, Chen M, Marshall JF and O'Toole EA (2015). Suppression of TGFβ and Angiogenesis by Type VII Collagen in Cutaneous SCC. J Natl Cancer Inst vol. 108, (1)
Gopinathan G, Milagre C, Pearce OMT, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F (2015). Interleukin-6 Stimulates Defective Angiogenesis. American Association for Cancer Research (AACR) Cancer Research vol. 75, (15) 3098-3107.
Gopinathan G, Milagre C, Pearce OMT, Reynolds L, Hodivala-Dilke K, Leinster A, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR and Balkwill F (2015). Abstract 4162: Interleukin–6 stimulates defective angiogenesis. American Association for Cancer Research (AACR)
Wong P-P, Demircioglu F, Ghazaly E, Alrawashdeh W, Stratford MRL, Scudamore CL, Cereser B, Crnogorac-Jurcevic T, McDonald S, Elia G, Hagemann T, Kocher HM and Hodivala-Dilke KM (2015). Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and Spread. Elsevier Cancer Cell vol. 27, (1) 123-137.
Birdsey GM, Shah AV, Dufton N, Reynolds LE, Almagro LO, Yang Y, Aspalter IM, Khan ST, Mason JC, Dejana E, Göttgens B, Hodivala-Dilke K, Gerhardt H, Adams RH and Randi AM (2015). The Endothelial Transcription Factor ERG Promotes Vascular Stability and Growth through Wnt/β-Catenin Signaling. Elsevier Developmental Cell vol. 32, (1) 82-96.
2014
Tavora B, Batista S, Alexopoulou AN, Kostourou V, Fernandez I, Robinson SD, Lees DM, Serrels B and Hodivala-Dilke K (2014). Generation of point-mutant FAK knockin mice. Genesis vol. 52, (11) 907-915.
Tavora B, Reynolds LE, Batista S, Demircioglu F, Fernandez I, Lechertier T, Lees DM, Wong P-P, Alexopoulou A, Elia G, Clear A, Ledoux A, Hunter J, Perkins N, Gribben JG and Hodivala-Dilke KM (2014). Endothelial-cell FAK targeting sensitizes tumours to DNA-damaging therapy. Nature vol. 514, (7520) 112-116.
Batista S, Maniati E, Reynolds LE, Tavora B, Lees DM, Fernandez I, Elia G, Casanovas O, Lo Celso C, Hagemann T and Hodivala-Dilke K (2014). Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis. Nat Commun vol. 5,
Alexopoulou AN, Ho-Yen CM, Papalazarou V, Elia G, Jones JL and Hodivala-Dilke K (2014). Tumour-associated endothelial-FAK correlated with molecular sub-type and prognostic factors in invasive breast cancer. BMC Cancer vol. 14,
Steri V, Ellison TS, Gontarczyk AM, Weilbaecher K, Schneider JG, Edwards D, Fruttiger M, Hodivala-Dilke KM and Robinson SD (2014). Acute depletion of endothelial β3-integrin transiently inhibits tumor growth and angiogenesis in mice. American Heart Association Circulation Research vol. 114, (1) 79-91.
Shah AV, Birdsey GM, Reynolds LE, Dufton N, Almagro LO, Yang Y, Aspalter IM, Khan ST, Mason JC, Dejana E, Goettgens B, Hodivala-Dilke K, Gerhardt H, Adams RH and Randi AM (2014). The endothelial transcription factor ERG promotes vascular stability and growth through Wnt/β-catenin signaling. ANGIOGENESIS vol. 17, (3) 715-715.
2013
Martino-Echarri E, Fernández-Rodríguez R, Rodríguez-Baena FJ, Barrientos-Durán A, Torres-Collado AX, Plaza-Calonge MDC, Amador-Cubero S, Cortés J, Reynolds LE, Hodivala-Dilke KM and Rodríguez-Manzaneque JC (2013). Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. Int J Cancer vol. 133, (10) 2315-2324.
Ma Y, Reynolds LE, Li A, Stevenson RP, Hodivala-Dilke KM, Yamashiro S and Machesky LM (2013). Fascin 1 is dispensable for developmental and tumour angiogenesis. Biol Open vol. 2, (11) 1187-1191.
Jones DT, Lechertier T, Reynolds LE, Mitter R, Robinson SD, Kirn-Safran CB and Hodivala-Dilke KM (2013). Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice. Dis Model Mech vol. 6, (1) 115-124.
Baker M, Reynolds LE, Robinson SD, Lees DM, Parsons M, Elia G and Hodivala-Dilke K (2013). Stromal Claudin14-heterozygosity, but not deletion, increases tumour blood leakage without affecting tumour growth. PLoS One vol. 8, (5)
Kostourou V, Lechertier T, Reynolds LE, Lees DM, Baker M, Jones DT, Tavora B, Ramjaun AR, Birdsey GM, Robinson SD, Parsons M, Randi AM, Hart IR and Hodivala-Dilke K (2013). FAK-heterozygous mice display enhanced tumour angiogenesis. Nat Commun vol. 4,
2012
Lechertier T and Hodivala-Dilke K (2012). Focal adhesion kinase and tumour angiogenesis. J Pathol vol. 226, (2) 404-412.
Jones DT, Lechertier T, Mitter R, Herbert JMJ, Bicknell R, Jones JL, Li J-L, Buffa F, Harris AL and Hodivala-Dilke K (2012). Gene expression analysis in human breast cancer associated blood vessels. PLoS One vol. 7, (10)
2011
Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, D'Amico G, Jones DT, Vojnovic B and Hodivala-Dilke K (2011). Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc vol. 7, (1) 89-104.
Robinson SD and Hodivala-Dilke KM (2011). The role of β3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol vol. 23, (5) 630-637.
Hodivala-Dilke KM (2011). Abstract SY16-03: Dose matters and angiogenesis. American Association for Cancer Research (AACR) Cancer Research vol. 71, (8_Supplement)
Baker M, Robinson SD, Hodivala-Dilke K and Ben-Yosef T (2011). Abstract 3479: Claudin-14: A novel regulator of angiogenesis. American Association for Cancer Research (AACR) Cancer Research vol. 71, (8_Supplement) 3479-3479.
Batista SA, Reynolds L, Tavora B and Hodivala-Dilke K (2011). Abstract 517: Deficiency of FAK in the bone marrow compartment enhances tumour metastasis. American Association for Cancer Research (AACR) Cancer Research vol. 71, (8_Supplement) 517-517.
Hodivala-Dilke KM (2011). Dose matters and angiogenesis. CANCER RESEARCH vol. 71,
Tavora B, Batista S and Hodivala-Dilke K (2011). Measuring angiogenesis in mice. Methods Mol Biol vol. 769, 351-358.
2010
Tavora B, Batista S, Reynolds LE, Jadeja S, Robinson S, Kostourou V, Hart I, Fruttiger M, Parsons M and Hodivala-Dilke KM (2010). Endothelial FAK is required for tumour angiogenesis. EMBO Mol Med vol. 2, (12) 516-528.
da Silva RG, Tavora B, Robinson SD, Reynolds LE, Szekeres C, Lamar J, Batista S, Kostourou V, Germain MA, Reynolds AR, Jones DT, Watson AR, Jones JL, Harris A, Hart IR, Iruela-Arispe ML, Dipersio CM, Kreidberg JA and Hodivala-Dilke KM (2010). Endothelial alpha3beta1-integrin represses pathological angiogenesis and sustains endothelial-VEGF. Am J Pathol vol. 177, (3) 1534-1548.
Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams RH, Fisher EMC, Tybulewicz VLJ, Hart IR and Hodivala-Dilke KM (2010). Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome (Corrigendum). NATURE vol. 466, (7304)
Reynolds LE, Watson AR, Baker M, Jones TA, D'Amico G, Robinson SD, Joffre C, Garrido-Urbani S, Rodriguez-Manzaneque JC, Martino-Echarri E, Aurrand-Lions M, Sheer D, Dagna-Bricarelli F, Nizetic D, McCabe CJ, Turnell AS, Kermorgant S, Imhof BA, Adams R, Fisher EMC, Tybulewicz VLJ, Hart IR and Hodivala-Dilke KM (2010). Tumour angiogenesis is reduced in the Tc1 mouse model of Down's syndrome. Nature vol. 465, (7299) 813-817.
Worth DC, Hodivala-Dilke K, Robinson SD, King SJ, Morton PE, Gertler FB, Humphries MJ and Parsons M (2010). Alpha v beta3 integrin spatially regulates VASP and RIAM to control adhesion dynamics and migration. J Cell Biol vol. 189, (2) 369-383.
D'Amico G, Robinson SD, Germain M, Reynolds LE, Thomas GJ, Elia G, Saunders G, Fruttiger M, Tybulewicz V, Mavria G and Hodivala-Dilke KM (2010). Endothelial-Rac1 is not required for tumor angiogenesis unless alphavbeta3-integrin is absent. PLoS One vol. 5, (3)
Watson AR, Pitchford SC, Reynolds LE, Direkze N, Brittan M, Alison MR, Rankin S, Wright NA and Hodivala-Dilke KM (2010). Deficiency of bone marrow beta3-integrin enhances non-functional neovascularization. J Pathol vol. 220, (4) 435-445.
Germain M, De Arcangelis A, Robinson SD, Baker M, Tavora B, D'Amico G, Silva R, Kostourou V, Reynolds LE, Watson A, Jones JL, Georges-Labouesse E and Hodivala-Dilke K (2010). Genetic ablation of the alpha 6-integrin subunit in Tie1Cre mice enhances tumour angiogenesis. J Pathol vol. 220, (3) 370-381.
D'Amico G, Jones DT, Nye E, Sapienza K, Ramjuan AR, Reynolds LE, Robinson SD, Kostourou V, Martinez D, Aubyn D, Grose R, Thomas GJ, Spencer-Dene B, Zicha D, Davies D, Tybulewicz V and Hodivala-Dilke KM (2010). Regulation of lymphatic-blood vessel separation by endothelial Rac1 (vol 136, pg 4043, 2009). DEVELOPMENT vol. 137, (2) 359-359.
2009
Robinson SD, Reynolds LE, Kostourou V, Reynolds AR, da Silva RG, Tavora B, Baker M, Marshall JF and Hodivala-Dilke KM (2009). Alphav beta3 integrin limits the contribution of neuropilin-1 to vascular endothelial growth factor-induced angiogenesis. J Biol Chem vol. 284, (49) 33966-33981.
D'Amico G, Jones DT, Nye E, Sapienza K, Ramjuan AR, Reynolds LE, Robinson SD, Kostourou V, Martinez D, Aubyn D, Grose R, Thomas GJ, Spencer-Dene B, Zicha D, Davies D, Tybulewicz V and Hodivala-Dilke KM (2009). Regulation of lymphatic-blood vessel separation by endothelial Rac1. Development vol. 136, (23) 4043-4053.
Reynolds AR and Hodivala-Dilke KM (2009). Will integrin inhibitors have proangiogenic effects in the clinic? Reply. NAT MED vol. 15, (7) 727-727.
Reynolds AR, Hart IR, Watson AR, Welti JC, Silva RG, Robinson SD, Da Violante G, Gourlaouen M, Salih M, Jones MC, Jones DT, Saunders G, Kostourou V, Perron-Sierra F, Norman JC, Tucker GC and Hodivala-Dilke KM (2009). Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nat Med vol. 15, (4) 392-400.
Ramjaun AR and Hodivala-Dilke K (2009). The role of cell adhesion pathways in angiogenesis. Int J Biochem Cell Biol vol. 41, (3) 521-530.
2008
Hodivala-Dilke K (2008). alpha v beta 3 integrin and angiogenesis: a moody integrin in a changing environment. CURR OPIN CELL BIOL vol. 20, (5) 514-519.
Silva R, D'Amico G, Hodivala-Dilke KM and Reynolds LE (2008). Integrins - The keys to unlocking angiogenesis. ARTERIOSCL THROM VAS vol. 28, (10) 1703-1713.
Schier S, Watson A, Hodivala-Dilke K and Wright NA (2008). The role of beta 3-integrin on bone marrow-derived cells in inflammatory bowel diseases. GASTROENTEROLOGY vol. 134, (4) A257-A257.
Reynolds LE, Conti FJ, Silva R, Robinson SD, Iyer V, Rudling R, Cross B, Nye E, Hart IR, Dipersio CM and Hodivala-Dilke KM (2008). alpha3beta1 integrin-controlled Smad7 regulates reepithelialization during wound healing in mice. J Clin Invest vol. 118, (3) 965-974.
Claxton S, Kostourou V, Jadeja S, Chambon P, Hodivala-Dilke K and Fruttiger M (2008). Efficient, inducible Cre-recombinase activation in vascular endothelium. GENESIS vol. 46, (2) 74-80.
Scott AN, Hetheridge C, Reynolds AR, Nayak V, Hodivala-Dilke K and Mellor H (2008). Farnesyltransferase inhibitors target multiple endothelial cell functions in angiogenesis. Angiogenesis vol. 11, (4) 337-346.
2007
Boosani CS, Mannam AP, Cosgrove D, Silva R, Hodivala-Dilke KM, Keshamouni VG and Sudhakar A (2007). Regulation of COX-2-mediated signaling by alpha 3 type IV noncollagenous domain in tumor angiogenesis. BLOOD vol. 110, (4) 1168-1177.
Piqueras L, Reynolds AR, Hodivala-Dilke KM, Alfranca A, Redondo JM, Hatae T, Tanabe T, Warner TD and Bishop-Bailey D (2007). Activation of PPARbeta/delta induces endothelial cell proliferation and angiogenesis. Arterioscler Thromb Vasc Biol vol. 27, (1) 63-69.
2006
Lucas M, Stuart LM, Zhang A, Hodivala-Dilke K, Febbraio M, Silverstein R, Savill J and Lacy-Hulbert A (2006). Requirements for apoptotic cell contact in regulation of macrophage responses. J IMMUNOL vol. 177, (6) 4047-4054.
Direkze NC, Jeffery R, Hodivala-Dilke K, Hunt T, Playford RJ, Elia G, Poulsom R, Wright NA and Alison MR (2006). Bone marrow-derived stromal cells express lineage-related messenger RNA species. Cancer Res vol. 66, (3) 1265-1269.
Robinson SD, Wilson S and Hodivala-Dilke KM (2006). Generation of genetically modified embryonic stem cells for the development of knockout mouse animal model systems. Methods Mol Med vol. 120, 465-477.
Reynolds LE and Hodivala-Dilke KM (2006). Primary mouse endothelial cell culture for assays of angiogenesis. Methods Mol Med vol. 120, 503-509.
2005
Fang J, Hodivala-Dilke K, Johnson BD, Du LM, Hynes RO, White GC and Wilcox DA (2005). Therapeutic expression of the platelet-specific integrin, alpha IIb beta 3, in a murine model for Glanzmann thrombasthenia. BLOOD vol. 106, (8) 2671-2679.
Lamagna C, Hodivala-Dilke KM, Imhof BA and Aurrand-Lions M (2005). Antibody against junctional adhesion molecule-C inhibits angiogenesis and tumor growth. CANCER RES vol. 65, (13) 5703-5710.
Reynolds LE, Conti FJ, Lucas M, Grose R, Robinson S, Stone M, Saunders G, Dickson C, Hynes RO, Lacy-Hulbert A and Hodivala-Dilke K (2005). Accelerated re-epithelialization in beta3-integrin-deficient- mice is associated with enhanced TGF-beta1 signaling. Nat Med vol. 11, (2) 167-174.
Brittan M, Braun KM, Reynolds LE, Conti FJ, Reynolds AR, Poulsom R, Alison MR, Wright NA and Hodivala-Dilke KM (2005). Bone marrow cells engraft within the epidermis and proliferate in vivo with no evidence of cell fusion. J Pathol vol. 205, (1) 1-13.
2004
McLean GW, Komiyama NH, Serrels B, Asano H, Reynolds L, Conti F, Hodivala-Dilke K, Metzger D, Chambon P, Grant SGN and Frame MC (2004). Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. Genes Dev vol. 18, (24) 2998-3003.
Direkze NC, Hodivala-Dilke K, Jeffery R, Hunt T, Poulsom R, Oukrif D, Alison MR and Wright NA (2004). Bone marrow contribution to tumor-associated myofibroblasts and fibroblasts. Cancer Res vol. 64, (23) 8492-8495.
Reynolds AR, Reynolds LE, Nagel TE, Lively JC, Robinson SD, Hicklin DJ, Bodary SC and Hodivala-Dilke KM (2004). Elevated Flk1 (vascular endothelial growth factor receptor 2) signaling mediates enhanced angiogenesis in beta3-integrin-deficient mice. Cancer Res vol. 64, (23) 8643-8650.
Robinson SD, Reynolds LE, Wyder L, Hicklin DJ and Hodivala-Dilke KM (2004). Beta3-integrin regulates vascular endothelial growth factor-A-dependent permeability. Arterioscler Thromb Vasc Biol vol. 24, (11) 2108-2114.
2003
Mistry A, Harbottle R, Hart S and Hodivala-Dilke KM (2003). Integrins and angiogenesis: unlocking the route to gene therapy. Curr Opin Mol Ther vol. 5, (6) 603-610.
Petiot A, Conti FJA, Grose R, Revest J-M, Hodivala-Dilke KM and Dickson C (2003). A crucial role for Fgfr2-IIIb signalling in epidermal development and hair follicle patterning. Development vol. 130, (22) 5493-5501.
Alugupalli KR, Michelson AD, Joris I, Schwan TG, Hodivala-Dilke K, Hynes RO and Leong JM (2003). Spirochete-platelet attachment and thrombocytopenia in murine relapsing fever borreliosis. Blood vol. 102, (8) 2843-2850.
Wan H, Stone MG, Simpson C, Reynolds LE, Marshall JF, Hart IR, Hodivala-Dilke KM and Eady RAJ (2003). Desmosomal proteins, including desmoglein 3, serve as novel negative markers for epidermal stem cell-containing population of keratinocytes. J Cell Sci vol. 116, (Pt 20) 4239-4248.
Hodivala-Dilke KM, Reynolds AR and Reynolds LE (2003). Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res vol. 314, (1) 131-144.
Conti FJA, Rudling RJ, Robson A and Hodivala-Dilke KM (2003). alpha3beta1-integrin regulates hair follicle but not interfollicular morphogenesis in adult epidermis. J Cell Sci vol. 116, (Pt 13) 2737-2747.
Reynolds AR, Moein Moghimi S and Hodivala-Dilke K (2003). Nanoparticle-mediated gene delivery to tumour neovasculature. Trends Mol Med vol. 9, (1) 2-4.
Direkze NC, Forbes SJ, Brittan M, Hunt T, Jeffery R, Preston SL, Poulsom R, Hodivala-Dilke K, Alison MR and Wright NA (2003). Multiple organ engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-marrow-transplanted mice. Stem Cells vol. 21, (5) 514-520.
2002
Wan H, Marshall J, Reynolds LE, Stone MG, McGrath JA, Hodivala-Dilke KM and Eady RAJ (2002). Diversity of desmoplakin expression in basal palm keratinocytes: A possible clue to the identification of epidermal stem cells. J INVEST DERMATOL vol. 119, (3) 714-714.
Schulz O, Pennington DJ, Hodivala-Dilke K, Febbraio M and Reis e Sousa C (2002). CD36 or alphavbeta3 and alphavbeta5 integrins are not essential for MHC class I cross-presentation of cell-associated antigen by CD8 alpha+ murine dendritic cells. J Immunol vol. 168, (12) 6057-6065.
Francis SE, Goh KL, Hodivala-Dilke K, Bader BL, Stark M, Davidson D and Hynes RO (2002). Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol vol. 22, (6) 927-933.
Brittan M, Hunt T, Jeffery R, Poulsom R, Forbes SJ, Hodivala-Dilke K, Goldman J, Alison MR and Wright NA (2002). Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. Gut vol. 50, (6) 752-757.
Forbes SJ, Hunt T, Brittan M, Jeffery R, Poulsom R, Hodivala-Dilke K, Alison MR and Wright NA (2002). Bone marrow derivation of pericryptal myofibroblasts in the mouse and human small intestine and colon. GUT vol. 50, A35-A35.
Brittan M, Hunt T, Jeffery R, Poulsom R, Forbes S, Hodivala-Dilke K, Alison M and Wright NA (2002). Bone marrow derivation of intestinal subepithelial myofibroblasts in the mouse and human small intestine and colon. GASTROENTEROLOGY vol. 122, (4) A95-A96.
Hodivala-Dilke K (2002). Primary mouse keratinocyte culture. Methods Mol Biol vol. 188, 139-144.
Reynolds LE, Wyder L, Lively JC, Taverna D, Robinson SD, Huang X, Sheppard D, Hynes RO and Hodivala-Dilke KM (2002). Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins. Nat Med vol. 8, (1) 27-34.
Hynes RO, Lively JC, McCarty JH, Taverna D, Francis SE, Hodivala-Dilke K and Xiao Q (2002). The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol vol. 67, 143-153.
2001
Hodivala-Dilke K (2001). Sticky science is skin deep. The Company of Biologists Journal of Cell Science vol. 114, (20) 3582-3582.
Forbes SJ, Wyles SM, Ryan ED, Navaratnarasah S, Hodivala-Dilke KM, Jeffrey R, Hunt T, Alison MR, Cook T, Pusey C, Poulsom R and Wright NA (2001). Kidney from bone marrow in humans and mice. J PATHOL vol. 195, 3A-3A.
Poulsom R, Forbes SJ, Hodivala-Dilke K, Ryan E, Wyles S, Navaratnarasah S, Jeffery R, Hunt T, Alison M, Cook T, Pusey C and Wright NA (2001). Bone marrow contributes to renal parenchymal turnover and regeneration. J Pathol vol. 195, (2) 229-235.
Forbes SJ, Alison MR, Hodivala-Dilke KM, Jeffery R, Poulsom R and Wright NA (2001). Bone marrow stem cells make hepatocytes with replicative potential. GASTROENTEROLOGY vol. 120, (5) A62-A62.
Forbes SJ, Hodivala-Dilke KM, Jeffery R, Alison MR, Poulsom R, Thomas H and Wright NA (2001). Hepatocytes derived from bone marrow stem cells demonstrate polyploidisation. J HEPATOL vol. 34, 20-21.
Forbes SJ, Hodivala-Dilke KM, Jeffery R, Hunt T, Alison MR, Poulsom R and Wright NA (2001). Hepatocytes derived from bone marrow stem cells show polyploidization in humans and mice. GUT vol. 48, A65-A66.
2000
Lively JC, Hodivala-Dilke K and Hynes RO (2000). In vitro characterization of integrin-deficient endothelial cells and aortic explants. MOL BIOL CELL vol. 11, 51A-51A.
McHugh KP, Hodivala-Dilke K, Zheng M-H, Namba N, Lam J, Novack D, Feng X, Ross FP, Hynes RO and Teitelbaum SL (2000). Mice lacking β3 integrins are osteosclerotic because of dysfunctional osteoclasts. American Society for Clinical Investigation Journal of Clinical Investigation vol. 105, (4) 433-440.
1999
Hynes RO, Bader BL and Hodivala-Dilke K (1999). Integrins in vascular development. FapUNIFESP (SciELO) Brazilian Journal of Medical and Biological Research vol. 32, (5) 501-510.
Hodivala-Dilke KM, McHugh KP, Tsakiris DA, Rayburn H, Crowley D, Ullman-Culleré M, Ross FP, Coller BS, Teitelbaum S and Hynes RO (1999). β3-integrin–deficient mice are a model for Glanzmann thrombasthenia showing placental defects and reduced survival. American Society for Clinical Investigation Journal of Clinical Investigation vol. 103, (2) 229-238.
Hynes RO and Hodivala-Dilke KM (1999). Insights and Questions Arising from Studies of a Mouse Model of Glanzmann Thrombasthenia. Thieme Thrombosis and Haemostasis vol. 82, (02) 481-485.
Tsakiris DA, Scudder L, Hodivala-Dilke K, Hynes RO and Coller BS (1999). Hemostasis in the Mouse (Mus musculus): A Review. Thieme Thrombosis and Haemostasis vol. 81, (02) 177-188.
1998
Hodivala-Dilke KM, DiPersio CM, Kreidberg JA and Hynes RO (1998). Novel Roles for α3β1 Integrin as a Regulator of Cytoskeletal Assembly and as a Trans-dominant Inhibitor of Integrin Receptor Function in Mouse Keratinocytes. Rockefeller University Press Journal of Cell Biology vol. 142, (5) 1357-1369.
1997
DiPersio CM, HodivalaDilke KM, Jaenisch R, Kreidberg JA and Hynes RO (1997). alpha 3 beta 1 integrin is required for normal development of the epidermal basement membrane. J CELL BIOL vol. 137, (3) 729-742.
1995
Braga VMM, Hodivala KJ and Watt FM (1995). Calcium-Induced Changes in Distribution and Solubility of Cadherins, Integrins and Their Associated Cytoplasmic Proteins in Human Keratinocytes. Taylor & Francis Cell Communication & Adhesion vol. 3, (3) 201-215.
1994
Watt FM and Hodivala KJ (1994). Cell Adhesion: Fibronectin and integrin knockouts come unstuck. Elsevier Current Biology vol. 4, (3) 270-272.
Hodivala KJ, Pei XF, Liu QY, Jones PH, Rytina ER, Gilbert C, Singer A and Watt FM (1994). Integrin expression and function in HPV 16-immortalised human keratinocytes in the presence or absence of v-Ha-ras. Comparison with cervical intraepithelial neoplasia. Oncogene vol. 9, (3) 943-948.
Hodivala K and Watt F (1994). Evidence that cadherins play a role in the downregulation of integrin expression that occurs during keratinocyte terminal differentiation. Rockefeller University Press Journal of Cell Biology vol. 124, (4) 589-600.
1991
Billingsley PF, Hodivala KJ, Winger LA and Sinden RE (1991). Detection of mature malaria infections in live mosquitoes. Oxford University Press (OUP) Transactions of the Royal Society of Tropical Medicine and Hygiene vol. 85, (4) 450-453.
1990
SUHRBIER A, WINGER L, O'DOWD C, HODIVALA K and SINDEN RE (1990). An antigen specific to the liver stage of rodent malaria recognized by a monoclonal antibody. Wiley Parasite Immunology vol. 12, (4‐5) 473-481.
Sinden RE, Suhrbier A, Davies CS, Fleck SL, Hodivala K and Nicholas JC (1990). The development and routine application of high-density exoerythrocytic-stage cultures of Plasmodium berghei. Bulletin of the World Health Organization vol. 68 Suppl, (Suppl) 115-125.
Winger L, Suhrbier A, O'Dowd CA, Hodivala KJ and Sinden RE (1990). A liver-stage specific antigen of P. berghei identified by a monoclonal antibody. Bulletin of the World Health Organization vol. 68 Suppl, (Suppl) 172-177.
1989
Suhrbier A, Wiser MF, Winger L, Harte P, Newton MF, Hodivala KJ, Nicholas J and Sinden RE (1989). Contrasts in antigen expression in the erythrocytic and exoerythrocytic stages of rodent malaria. Cambridge University Press (CUP) Parasitology vol. 99, (2) 165-170.
Grants
Imaging tools for the early signposting of treatment resistance and metastasis
Kairbaan Hodivala-Dilke
£249,477 CR-UK Cancer Research UK (01-01-2025 - 30-06-2027)
Kairbaan Hodivala-Dilke
£249,477 CR-UK Cancer Research UK (01-01-2025 - 30-06-2027)
Exploiting the effects of mural cell b3-integrin expression in the control of cancer growth, resistan
Kairbaan Hodivala-Dilke
£1,798,616 CR-UK Cancer Research UK (01-11-2021 - 31-10-2026)
Kairbaan Hodivala-Dilke
£1,798,616 CR-UK Cancer Research UK (01-11-2021 - 31-10-2026)
Novel Combination Strategies for the Improved Treatment of Lung Cancer
Kairbaan Hodivala-Dilke
£445,614 Barts and the London Charity (19-04-2021 - 18-11-2025)
Kairbaan Hodivala-Dilke
£445,614 Barts and the London Charity (19-04-2021 - 18-11-2025)
Investigating the role of vascular endothelial-cell senescence driving resistance to DNA-damaging therapies and metastasis formation in lung cancer
Kairbaan Hodivala-Dilke
£536,663 MRC Medical Research Council (01-01-2021 - 23-09-2025)
Kairbaan Hodivala-Dilke
£536,663 MRC Medical Research Council (01-01-2021 - 23-09-2025)
Reducing pancreatic cancer metastasis by targetting the endothelial cell niche
Kairbaan Hodivala-Dilke
£200,000 PCRF Pancreatic Cancer Research Fund (01-04-2020 - 28-02-2026)
Kairbaan Hodivala-Dilke
£200,000 PCRF Pancreatic Cancer Research Fund (01-04-2020 - 28-02-2026)
Development of endothelial targeting antibody-PROTAC conjugate for improved sensitisation to DNA-dam -Resub
Kairbaan Hodivala-Dilke
£27,740 Barts and the London Charity (01-08-2023 - 01-10-2024)
Kairbaan Hodivala-Dilke
£27,740 Barts and the London Charity (01-08-2023 - 01-10-2024)
Investigating the effect of CDK7i on PDAC -Carrick Therapeutics
Kairbaan Hodivala-Dilke
£25,072 Carrick Therapeutics Limited (01-12-2022 - 30-11-2023)
Kairbaan Hodivala-Dilke
£25,072 Carrick Therapeutics Limited (01-12-2022 - 30-11-2023)
Targeting radiation-induced vascular dysfunction and inflammation to modulate responses to therapy
Kairbaan Hodivala-Dilke
£43,768 CR-UK Cancer Research UK (01-09-2022 - 31-08-2023)
Kairbaan Hodivala-Dilke
£43,768 CR-UK Cancer Research UK (01-09-2022 - 31-08-2023)
Establishing Radiation Research Infrastructure at QMUL
Kairbaan Hodivala-Dilke
£49,788 Barts and the London Charity (01-01-2022 - 31-12-2022)
Kairbaan Hodivala-Dilke
£49,788 Barts and the London Charity (01-01-2022 - 31-12-2022)
Targeting the tumour microenvironment to enhance immunotherapy: A cross-disciplinary approach to ass
Kairbaan Hodivala-Dilke
£7,000 CR-UK Cancer Research UK (01-07-2021 - 30-06-2022)
Kairbaan Hodivala-Dilke
£7,000 CR-UK Cancer Research UK (01-07-2021 - 30-06-2022)
Manipulating the tumour endothelium and effects on enhancing radiotherapy
Kairbaan Hodivala-Dilke
£381,144 CR-UK Cancer Research UK (01-10-2020 - 30-09-2024)
Kairbaan Hodivala-Dilke
£381,144 CR-UK Cancer Research UK (01-10-2020 - 30-09-2024)
Enhancing radiotherapy sensitisation and improving cancer control by modulating tumour microenvironment derived angiocrine signalling
Kairbaan Hodivala-Dilke
£145,664 CR-UK Cancer Research UK (28-09-2020 - 27-09-2024)
Kairbaan Hodivala-Dilke
£145,664 CR-UK Cancer Research UK (28-09-2020 - 27-09-2024)
Improving the efficacy of immunotherapy in advanced lung cancer
Kairbaan Hodivala-Dilke
£208,131 Worldwide Cancer Research (01-04-2019 - 21-09-2023)
Kairbaan Hodivala-Dilke
£208,131 Worldwide Cancer Research (01-04-2019 - 21-09-2023)
PhD Studentship - Dukinfield
Kairbaan Hodivala-Dilke
£36,000 BHF British Heart Foundation (01-08-2017 - 30-09-2018)
Kairbaan Hodivala-Dilke
£36,000 BHF British Heart Foundation (01-08-2017 - 30-09-2018)
Targeting tumour blood vessels to alter angiocrine factors and enhance chemosensitisation
Kairbaan Hodivala-Dilke
£148,986 CR-UK Cancer Research UK (01-10-2015 - 30-09-2019)
Kairbaan Hodivala-Dilke
£148,986 CR-UK Cancer Research UK (01-10-2015 - 30-09-2019)
Targeting tumour blood vessels to alter angiocrine factors and enhance chemossensitisation
Kairbaan Hodivala-Dilke
£2,638,598 CR-UK Cancer Research UK (01-10-2015 - 31-07-2022)
Kairbaan Hodivala-Dilke
£2,638,598 CR-UK Cancer Research UK (01-10-2015 - 31-07-2022)